List View Detail View 51-75 of 107 items Sort by: Best Match Name Clone Applications Regulatory Status Previous 1 2 3 4 ... 5 Next Product Clone Appl. Reg Cat# Size GoInVivo™ Purified anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313541 5 mg ¥110,880 313542 25 mg お問い合わせください 313543 50 mg お問い合わせください 313544 100 mg お問い合わせください 313545 500 mg お問い合わせください 313546 1 g お問い合わせください Ultra-LEAF™ Purified anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC, IP, Costim RUO 313539 100 µg ¥32,870 313540 1 mg ¥105,080 Ultra-LEAF™ Purified anti-human/mouse/rat CD278 (ICOS) Recombinant Antibody QA17A10 FC RUO 395103 100 µg ¥52,130 395104 1 mg ¥123,340 Ultra-LEAF™ Purified anti-human/mouse/rat CD278 (ICOS) Recombinant Antibody QA17A31 FC RUO 396503 100 µg ¥52,130 396504 1 mg ¥115,040 Pacific Blue™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313521 25 µg ¥23,320 APC/Fire™ 750 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313535 25 µg ¥31,020 313536 100 µg ¥78,760 Alexa Fluor® 488 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC, SB RUO 313514 100 µg ¥50,380 Alexa Fluor® 700 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313528 100 µg ¥55,660 TotalSeq™-D0171 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A PG RUO 313561 10 µg ¥81,180 Brilliant Violet 605™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313537 25 tests ¥37,620 313538 100 tests ¥96,800 Brilliant Violet 750™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313557 25 tests ¥37,620 Brilliant Violet 711™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313547 25 tests ¥43,560 Brilliant Violet 421™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313524 100 tests ¥94,380 Brilliant Violet 650™ anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC RUO 313550 100 tests ¥96,800 Alexa Fluor® 647 anti-human/mouse/rat CD278 (ICOS) Antibody C398.4A FC, IHC-F RUO 313515 25 µg ¥20,460 See more size options for this product on the next page. Results Per Page: 25 50 100 200 Previous 1 2 3 4 ... 5 Next
Follow Us